|
1
|
Donzelli M, Derungs A, Serratore MG,
Noppen C, Nezic L, Krähenbühl S and Haschke M: The basel cocktail
for simultaneous phenotyping of human cytochrome P450 isoforms in
plasma, saliva and dried blood spots. Clin Pharmacokinet.
53:271–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kennedy WK, Jann MW and Kutscher EC:
Clinically significant drug interactions with atypical
antipsychotics. CNS Drugs. 27:1021–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borba MA, Melo-Neto RP, Leitão GM,
Castelletti CH, Lima-Filho JL and Martins DB: Evaluating the impact
of missenses mutations in CYP2D6*7 and CYP2D6*14A: Does it
compromise tamoxifen metabolism? Pharmacogenomics. 17:573–582.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Werk AN, Lefeldt S, Bruckmueller H,
Hemmrich-Stanisak G, Franke A, Roos M, Küchle C, Steubl D,
Schmaderer C, Bräsen JH, et al: Identification and characterization
of a defective CYP3A4 genotype in a kidney transplant patient with
severely diminished tacrolimus clearance. Clin Pharmacol Ther.
95:416–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaudhry AS, Prasad B, Shirasaka Y, Fohner
A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, et al:
The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism
contributing to the poor metabolizer phenotype in livers with
CYP2C19*35 and CYP2C19*2 alleles. Drug Metab Dispos. 43:1226–1235.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fleeman N, McLeod C, Bagust A, Beale S,
Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom
S, et al: The clinical effectiveness and cost-effectiveness of
testing for cytochrome P450 polymorphisms in patients with
schizophrenia treated with antipsychotics: A systematic review and
economic evaluation. Health Technol Assess. 14:1–157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Brito RB, de Carvalho Araújo L, Diniz
MJA, de Castro Georg R, Nabout JC, Vianelo RP, da Silva Santos R,
da Silva Cruz AH and Ghedini PC: The CYP1A2 −163C > A
polymorphism is associated with super-refractory schizophrenia.
Schizophr Res. 169:502–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balibey H, Basoglu C, Lundgren S, Babaoglu
MO, Yasar U, Herken H, Rane A, Bozkurt A and Cetin M: CYP1A2*1F
polymorphism decreases clinical response to clozapine in patients
with schizophrenia. Bull Clin Psychopharmacol. 21:93–99. 2011.
View Article : Google Scholar
|
|
9
|
Fleeman N, Dundar Y, Dickson R, Jorgensen
A, Pushpakom S, McLeod C, Pirmohamed M and Walley T: Cytochrome
P450 testing for prescribing antipsychotics in adults with
schizophrenia: Systematic review and meta-analyses.
Pharmacogenomics J. 11:1–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pedersen RS, Damkier P, Christensen MM and
Brosen K: A cytochrome P450 phenotyping cocktail causing unexpected
adverse reactions in female volunteers. Eur J Clin Pharmacol.
69:1997–1999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohlrausch FB, Severino-Gama C, Lobato MI,
Belmonte-de-Abreu P, Carracedo A and Hutz MH: The CYP1A2 −163C >
A polymorphism is associated with clozapine-induced generalized
tonic-clonic seizures in Brazilian schizophrenia patients.
Psychiatry Res. 209:242–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woo YS, Wang HR, Yoon BH, Lee SY, Lee KH,
Seo JS and Bahk WY: Bioequivalence of generic and brand name
clozapine in Korean schizophrenic patients: A randomized,
two-period, crossover study. Psychiatry Investig. 12:356–360. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Satomi Y and Nishino H: Inhibition of the
enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by fucoxanthin,
a marine carotenoid. Oncol Lett. 6:860–864. 2013.PubMed/NCBI
|
|
14
|
Ivanova SA, Toshchakova VA, Filipenko ML,
Fedorenko OY, Boyarko EG, Boiko AS, Semke AV, Bokhan NA, Aftanas LI
and Loonen AJ: Cytochrome P450 1A2 co-determines neuroleptic load
and may diminish tardive dyskinesia by increased inducibility.
World J Biol Psychiatry. 16:200–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amini-Shirazi N, Ghahremani MH,
Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S,
Pakdaman H and Kebriaeezadeh A: Influence of CYP2C9 polymorphism on
metabolism of valproate and its hepatotoxin metabolite in Iranian
patients. Toxicol Mech Methods. 20:452–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan L, Yu JT, Sun YP, Ou JR, Song JH and
Yu Y: The influence of cytochrome oxidase CYP2A6, CYP2B6, and
CYP2C9 polymorphisms on the plasma concentrations of valproic acid
in epileptic patients. Clin Neurol Neurosurg. 112:320–323. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Albertson TE, Schivo M, Gidwani N, Kenyon
NJ, Sutter ME, Chan AL and Louie S: Pharmacotherapy of critical
asthma syndrome: Current and emerging therapies. Clin Rev Allergy
Immunol. 48:7–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miravitlles M and Soler-Cataluña JJ: GOLD
in 2017: A view from the Spanish COPD guidelines (GesCOPD). Arch
Bronconeumol. 53:89–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahmad A, Husain A, Mujeeb M, Khan SA,
Najmi AK, Siddique NA, Damanhouri ZA and Anwar F: A review on
therapeutic potential of Nigella sativa: A miracle herb. Asian Pac
J Trop Biomed. 3:337–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong N, Lin J, Mehta P, Ngamjanyaporn P,
Wu TC and Yunus F: Real-life effectiveness of budesonide/formoterol
maintenance and reliever therapy in asthma patients across Asia:
SMARTASIA study. BMC pulm med. 13:222013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burney P, Jarvis D and Perez-Padilla R:
The global burden of chronic respiratory disease in adults. Int J
Tuberc Lung Dis. 19:10–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shao W and He J: CYP1A2 rs2069514
polymorphism and lung cancer susceptibility: A meta-analysis. Ann
Transl Med. 4:212016.PubMed/NCBI
|
|
23
|
Dai DP, Li CB, Wang SH, Cai J, Geng PW,
Zhou YF, Hu GX and Cai JP: Identification and characterization of a
novel CYP2C9 allelic variant in a warfarin-sensitive patient.
Pharmacogenomics. 16:1475–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du J, Yu L, Wang L, Zhang A, Shu A, Xu L,
Xu M, Shi Y, Li X, Feng G, et al: Differences in CYP3A41G genotype
distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3
Chinese populations. Clin Chim Acta. 383:172–174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshinari K, Yoda N, Toriyabe T and
Yamazoe Y: Constitutive androstane receptor transcriptionally
activates human CYP1A1 and CYP1A2 genes through a common regulatory
element in the 5′-flanking region. Biochem Pharmacol. 79:261–269.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gunes A and Dahl ML: Variation in CYP1A2
activity and its clinical implications: Influence of environmental
factors and genetic polymorphisms. Pharmacogenomics. 9:625–637.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sansen S, Yano JK, Reynald RL, Schoch GA,
Griffin KJ, Stout CD and Johnson EF: Adaptations for the oxidation
of polycyclic aromatic hydrocarbons exhibited by the structure of
human P450 1A2. J Biol Chem. 282:14348–14355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hatta FH, Lundblad M, Ramsjo M, Kang JH,
Roh HK, Bertilsson L, Eliasson E and Aklillu E: Differences in
CYP2C9 genotype and enzyme activity between Swedes and Koreans of
relevance for personalized medicine: Role of ethnicity, genotype,
smoing, age and sex. OMICS. 19:346–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sutrisna E: The impact of CYP1A2 and
CYP2E1 genes polymorphism on theophylline response. J Clin Diagn
Res. 10:1–3. 2016.
|
|
30
|
Bloom J, Hinrichs AL, Wang JC, von Weymarn
LB, Kharasch ED, Bierut LJ, Goate A and Murphy SE: The contribution
of common CYP2A6 alleles to variation in nicotine metabolism among
European-Americans. Pharmacogenet Genomics. 21:403–416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shin J, Pauly DF, Pacanowski MA, Langaee
T, Frye RF and Johnson JA: Effect of cytochrome P450 3A5 genotype
on atorvastatin pharmacokinetics and its interaction with
clarithromycin. Pharmacotherapy. 31:942–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He BX, Shi L, Qiu J, Zeng XH and Zhao SJ:
The effect of CYP3A4*1G allele on the pharmacokinetics of
atorvastatin in Chinese Han patients with coronary heart disease. J
Clin Pharmacol. 54:462–467. 2014. View
Article : Google Scholar : PubMed/NCBI
|
